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Protein kinases control the function of about one third of cellular proteins by catalysing the 
transfer of the -phosphate group of ATP onto their substrate proteins. Protein phosphatases 
counter this action and also control the activation status of many kinases. Cellular responses to 
environmental changes, or signalling events, temporarily tilt the balance of protein 10 
phosphorylation and dephosphorylation to one side or the other. The identification of protein -
kinase substrate pairs and substrate-phosphatase pairs is critical to understanding cell function and 
how cells respond to environmental changes. Identification of these substrate-enzyme pairs is non-
trivial, because of the structural and mechanistic conservation of the catalytic cores of protein 
kinases. Here we review recent progress towards identifying protein kinase-substrate pairs by 15 
emphasising the use of chemical genetics and purpose-designed ATP analogues that target one 
particular protein kinase. In addition, we discuss activity-based chemical profiling approaches, 
based on ATP analogues, for the detection of active kinases.
A Introduction 
Protein kinases catalyse the transfer of the -phosphate group 20 
of ATP onto serine, threonine or tyrosine residues of substrate 
proteins (Scheme 1). Phosphorylation can have profound 
effects on the phosphorylated protein, altering its enzymatic 
activity, ability to recognize and interact with other proteins, 
or subcellular localization. Phosphatases remove phosphoryl 25 
groups, making phosphorylation a reversible modification. 
Consequentially, the balance of protein kinase and 
phosphatase activities controls the phosphorylation state of 
many, if not all, cellular proteins. Temporary perturbation of 
this balance when cells respond to stimuli is the basis for 30 
protein kinase/phosphatase-mediated signal transduction. 
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Scheme 1 Kinase-catalysed transfer of the -phosphoryl group from ATP 
to substrate residues.  
 The identification of kinase-substrate interactions is central 35 
to understanding phosphorylation-based. This task is 
complicated by the huge number of protein kinases and 
phosphorylated substrates involved. The human ‘kinome’ 
consists of 518 protein kinases and an estimated ~20,000 
phosphorylation events.1 The catalytic cores of kinases adopt 40 
a common, conserved fold and mechanism to catalyse -
phosphate transfer. This conservation complicates the 
identification of kinase-substrate pairs, because it makes it 
difficult to achieve selectivity for the -phosphate transfer 
reaction. In a cellular context, subcellular co-localization of a 45 
kinase and its substrate(s), and long-distance interactions 
between the kinase and its substrate(s) facilitate control over 
the selectivity of a particular protein kinase. Some 
approaches, notably the use of labelled ATP analogues, 
require cells to be lysed, because of the membrane 50 
impermeability of these hydrophilic molecules. Thus, the 
spatial control over kinase-substrate pairs is lost. For all these 
reasons faithful identification of all kinase-substrate pairs, 
especially those where the substrate is present at low 
abundance, is technically challenging. In this review we will 55 
summarise methods to identify these kinase-substrate pairs. 
Emphasis will be given to recently-developed chemical 
genetic approaches, and the structural and enzymological 
basis of these approaches. In addition, we will also discuss 
activity-based profiling of active protein kinases that employ 60 
chemical, ATP-based, probes for active protein kinases. 
B Classical approaches towards identifying 
kinase-substrate pairs 
The importance of kinase-substrate relationships has inspired 
many strategies towards identifying these pairs1 that can be 65 
classified into biochemical and genetic approaches. To 
appreciate the advantages of chemical genetic approaches 
over these classical approaches, we will first briefly 
summarize these classical approaches and their limitations. 
Biochemical approaches 70 
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Phosphorylation of potential substrates by a kinase is most 
often used to identify substrates for the kinase of interest. To 
identify substrates for a kinase, the kinase can be expressed in 
host cells such as bacteria, yeasts, or insect cells, and purified. 
The purified kinase can then be incubated with candidate 5 
substrate proteins, chosen on the basis of current knowledge 
or candidate libraries, and an ATP molecule labelled at the -
phosphate position. The -phosphate label often takes the 
form of a radioactive phosphate or a thiophosphate group, 
where the choice of label determines the strategy for detection 10 
and isolation of the substrate(s). Candidate substrates can be 
provided as individual, recombinantly expressed and purified 
proteins. Substrates can also be supplied as libraries displayed 
on phages, arrayed as peptides or complete proteins on chips 
or microtiter plates, or even as whole cell lysates or lysates of 15 
subcellular fractions. Successful phosphotransfer can then be 
demonstrated by a variety of methods such as autoradiography 
after gel electrophoresis or precipitation of the substrate and 
quantitative analysis of incorporated radioactivity by 
scintillation counting, followed by identification of the protein 20 
by mass spectrometry (MS)-based methods.  
 Expression of protein kinases is not always successful, 
necessitating purification and isolation of some kinases from 
cells or tissues. This, however, comes at the price of 
potentially introducing contaminating kinases into the assay. 25 
This problem can be addressed if a given kinase has been 
expressed as a recombinant protein because quantitative 
comparison of -phosphate incorporation catalysed by wild 
type (WT) and a catalytically inactive mutant can be used to 
exclude phosphorylation events catalysed by contaminating 30 
kinases. 
 Careful optimisation of the experimental conditions for -
phosphate transfer, such as using high concentrations of 
recombinant kinase, -32P-ATP of high specific activity, short 
incubation times, Mn2+ instead of Mg2+ as cofactor, and 35 
chromatographic fractionation of the extract before the 
kinasing reaction, often allows successful identification of 
kinase substrates. Adoption of this careful optimisation of 
reaction conditions, together with parallel analysis of several 
isoforms of a kinase to identify substrates preferentially 40 
phosphorylated by only one of the isoforms is the basis of the 
KESTREL method.2 
 The major concern with in vitro identification of kinase-
substrate pairs is identification of a large number of false-
positive substrates, because the loss of tight control over the 45 
kinases that is present in cells in vivo often leads to 
promiscuous substrate phosphorylation.2-4 Other limitations, 
such as non-specific adsorption of proteins to chips or 
nitrocellulose membranes and incorrect folding of 
recombinant proteins also need to be considered. Furthermore, 50 
for convenience, peptide analogues, rather than protein 
substrates, are often employed in in vitro studies, however, 
they often display KM values that are several orders of 
magnitude higher than their protein progenitors. 
 To identify kinase substrates in vivo substrates 55 
phosphorylated by a given protein kinase in response to a 
stimulus can be identified by incubating cells with radioactive 
phosphate and comparing the spectrum of proteins that 
incorporated the radioactive phosphate in the presence and in 
the absence of the stimulus. This approach often suffers from 60 
poor selectivity and the use of heroic amounts of radioactive 
phosphate. The use of phosphorylation-specific antibodies or 
phospho-specific binding domains5 allows enrichment of 
phosphopeptides and thus limits the need to use high doses of 
radioactivity. Antibodies with high affinity and specificity 65 
against phosphotyrosine are available, but preparation of 
antibodies of comparable quality against phosphoserine or 
phosphothreonine has been less successful.3 All of these 
approaches require careful, case-specific optimisation and 
further validation, for example through in vitro kinase assays, 70 
to ensure that substrates for the kinase of interest are 
genuinely identified. This is because activation of downstream 
kinases and secondary effects can easily lead to the 
identification of false positives. Identification of kinase 
substrates by in vivo phosphorylation of substrates in cells 75 
treated with a protein kinase inhibitor often leads to false 
positive results because kinase inhibitors usually target 
conserved ATP-binding/catalytic sites in a promiscuous 
manner.6, 7 
 Kinase-substrate pairs can also be identified by exploiting 80 
the, often transient, interaction between the kinase and its 
substrate by any kind of methodology that allows studying of 
protein-protein interactions, such as pull-down assays, co-
immunoprecipitation assays, cross-linking of kinase and 
substrate, yeast two-hybrid or split-ubiquitin assays. 85 
Interaction is not equivalent to phosphorylation, thus, 
substrates identified through interaction assays must be 
confirmed in phosphotransfer assays. 
 Instead of assaying for substrate phosphorylation, 
dephosphorylation of a phosphorylated substrate in the 90 
presence of high ADP concentrations can also be used to 
identify a kinase substrate.8 This approach exploits the 
principle that kinases, as catalysts, do not alter the equilibrium 
position of the phosphotransfer reaction and that, in 
consequence, the reaction can be drawn to the side of the 95 
reactants by provision of a huge excess of ADP over ATP. 
Genetic approaches 
Genetic approaches can also be used to identify kinase-
substrate pairs. These approaches are most advanced for lower 
eukaryotes such as the yeast Saccharomyces cerevisiae. 100 
However, these organisms do not harbour the full spectrum of 
orthologues of mammalian kinases or their substrates, thus, 
many potential kinases and substrates of biomedical 
significance are, necessarily, ‘missed’ when these model 
organisms are used. 105 
 In S. cerevisiae, synthetic genetic analysis (SGA) has been 
used to identify all pairwise genetic interactions between 
kinases, phosphatases, and their substrates9. SGA is based on 
robotic generation of mutant yeast cells that have two genes 
deleted, for example a kinase and its suspected (or known) 110 
substrate(s). Analysis then centres on quantification of a 
desired phenotype, usually growth on standard media. 
Comparison of phenotypes then allows the identification of 
aggravating, buffering, or neutral interactions between both 
mutations. 115 
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  3 
 A common limitation of loss-of-function-based genetic 
approaches, such as SGA, is that gene pairs/families with 
redundant or overlapping functions escape investigation, plus 
it is limited to mutations that maintain viability of the cells. In 
addition, the mutant cells may adapt and mask the desired 5 
phenotype. Redundant gene pairs/families can be studied 
using overexpression approaches,10 but the level of 
overexpression of a protein or a functional enzyme itself may 
introduce artefacts into the experimental system. In addition, 
genetic approaches do not provide information on whether an 10 
interaction is direct or indirect, in other words, mediated 
between the products of two interacting genes or by an 
unknown number of other proteins. The read-out of genetic 
interaction screens depends on the phenotype that is being 
investigated, meaning that many legitimate, but more subtle 15 
interactions that do not affect growth may not be uncovered in 
a screen for growth defects at normal growth temperatures. 
 Despite their limitations, classical biochemical and genetic 
approaches have made, and will continue to make, valuable 
contributions towards identifying kinase-substrate pairs. To 20 
obtain a complete picture of the kinome, the intrinsic 
shortcomings of classical approaches towards the 
identification of kinase-substrate pairs have to be addressed. 
Only then will reliable identification of all kinase-substrate 
pairs be possible, including the identification of those pairs 25 
where one or both partners are present at low abundance. 
Chemical genetics of protein kinases promises to fill this gap. 
Protein kinase chemical genetics combines the genetic 
engineering of a protein kinase and chemical synthesis of ATP 
analogues tailored as substrates or inhibitors towards only the 30 
engineered, or analogue-sensitised (as)-kinase, as it is known. 
This approach relies on our understanding of the mechanism 
of kinase-catalysed -phosphoryl group transfer from ATP 
onto substrates, binding of ATP to the active site, and 
synthetic strategies towards the preparation of ATP analogues. 35 
In the following sections we will briefly review the structure 
and catalytic mechanism of protein kinases, then discuss 
synthetic strategies towards ATP analogues and limitations of 
as-kinases, before concluding with examples of other 
chemical methods for understanding protein-kinase-mediated 40 
signalling pathways. 
C Structure and catalytic mechanism of the 
protein kinase domain 
The structures of the kinase domains of all eukaryotic protein 
kinases known to date are similar. This high degree of 45 
sequence conservation suggests that all eukaryotic protein 
kinases share a common structure and use similar mechanisms 
to catalyse -phosphate transfer.11  
 50 
Fig. 1 Ribbon diagrams of the X ray structure of PKA (PDB no. 1ATP). 
The N lobe is blue, the C lobe red, and the linker between the N and C 
lobes orange. The protein kinase inhibitor peptide PKI (5-24) is shown in 
green. The non-conserved helix B is in dark green, helix C in light 
blue and  sheets in the C lobe in dark orange. In the upper picture, 55 
helices and  sheets are labelled. In the lower picture residues involved in 
catalysis of -phosphate transfer and phosphorylated T197 positioned in 
the basic RD pocket formed by R165 and K189 are labelled. 
Structure 
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A typical protein kinase domain consists of two lobes, a small 
N-terminal lobe (the N lobe), primarily involved in ATP 
binding, and a large C-terminal lobe (C lobe) that is largely 
responsible for substrate binding and catalysis (Fig. 1), with 
an additional role in ATP binding. Comparison of the X-ray 5 
structures of protein kinase A (PKA), the cyclin-dependent 
kinase CDK2, and the mitogen-activated protein kinase 
ERK2, reveals a largely conserved fold for both lobes.4 The N 
lobe consists of a twisted five-stranded antiparallel -sheet 
and a lateral flanking C helix. The phosphate anchor 10 
(GxGxxG, x = any amino acid) is located in a loop between 
sheets 1 and 2. Sheet 3 harbours an invariant lysine, K72, 
and the C helix provides the invariant glutamate, E91. The 
‘phosphate anchor’ positions the - and -phosphates of ATP. 
The C lobe consists of four  strands and several  helices. Its 15 
important role in catalysis is illustrated by the presence of the 
‘catalytic loop’ between 6 and 7 of PKA (Fig. 1) and the 
Mg2+ loop between 8 and 9 in which an aspartate 
coordinating a Mg2+ ion, D184, is situated. The catalytic loop 
harbours K168, which contacts the -phosphate of ATP, and 20 
N171, which binds a second Mg2+ ion.  
 Another important feature of the kinase domain is the 
activation loop. The activation loop is located between the last 
 strand and helix F. Certain protein kinases possess a 
conserved arginine immediately preceding the catalytic 25 
aspartate (D166), a basic residue in strand 9, and basic 
residues in helix C. In these ‘RD kinases’ phosphorylation of 
serine, threonine, or tyrosine residues located in the activation 
loop induces positioning of the phosphorylated activation loop 
in to basic pockets.12 Activation loop movement can also be 30 
induced through interaction of the protein kinase with 
regulatory subunits, for example interaction of cyclin-
dependent kinases with cyclins.12 The activation loop gates 
access to the ATP or substrate binding pockets. Consequently, 
chemical probing for accessibility of the ATP binding pocket 35 
can be used to identify the set of active kinases in a certain 
situation, for example in cancer cells13 (cf. section E). 
 Several residues interact with ATP, however, those 
contributing to recognition of the adenine portion of ATP and 
the catalytic core for phosphoryl transfer are of most 40 
significance to chemical genetic studies and will be the 
primary focus here. Hydrogen bonds between the N7 nitrogen 
and the hydroxyl group of T183 and between the N6 nitrogen 
of the adenine ring and the backbone carbonyl of E121 bind 
the adenine ring in an otherwise hydrophobic pocket. L49, 45 
V123, and a large hydrophobic residue, M121 in PKA, 
contribute to this hydrophobic pocket. Filling-in the space 
created in kinase mutants in which the bulky, hydrophobic 
M121 residue has been replaced by a smaller amino acid using 
chemically synthesised adenine nucleotide analogues carrying 50 
a bulkier, hydrophobic adenine residue is the basis of protein 
kinase chemical genetics developed by Shokat and co-workers 
(Fig. 2). 
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Scheme 2 Mechanism of kinase-mediated phosphoryl transfer. A Protein 55 
kinase binding ATP and substrate in readiness for phosphoryl transfer. B 
Model of the phosphoryl transfer transition structure with a highly 
dissociative phosphoryl transfer and general base-assisted nucleophilic 
attack of an aliphatic (serine or threonine) or aromatic hydroxyl (tyrosine) 
group on the -phosphoryl group of ATP. C Products bound within the 60 
kinase active site. Models are based on11, 14 
Catalytic roles of conserved residues 
The catalytic mechanism for -phosphate transfer is highly 
dissociative (Scheme 2)11, meaning that bond breaking 
between the leaving group O-atom and the -phosphorus atom 65 
is more advanced than the formation of the bond between the 
O-atom of the incoming nucleophile and the -phosphorus 
atom in the transition structure. The first Mg2+ ion (Mg12+, 
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Scheme 2A) is involved in optimal positioning of the -
phosphate for attack by the incoming O-nucleophile or 
neutralization of the charges on the -phosphate to facilitate 
nucleophilic attack, or both. The second Mg2+ ion (Mg22+, 
Scheme 2A) is bound to N171, D184, a water molecule and 5 
the - and -phosphates of ATP. It has been proposed to act as 
a Lewis acid stabilising the negative charge formed on the 
oxygen atom by bridging the - and -phosphates in the 
transition structure (Scheme 2B).14 D166 forms a hydrogen 
bond with a hydroxyl group of an inhibitor peptide in crystal 10 
structures of PKA, suggesting that D166 orients the hydroxyl 
group on the substrate for nucleophilic attack,15 and 
subsequently acts as a general base that abstracts the proton 
from the hydroxyl group of the O-nucleophile late in the 
reaction14. The development of a large amount of negative 15 
charge on the O-nucleophile at an early point along the 
reaction co-ordinate may actually hinder attack on the -
phosphate because of charge repulsion between the 
(di)anionic -phosphate and the incoming nucleophile.16 The 
cationic K168 makes an electrostatic contact with the -20 
phosphate in PKA throughout the reaction, but is replaced by 
an arginine or even alanine in other protein kinases17. D184 is 
conserved in all kinases where it coordinates both Mg2+ ions. 
A mutation of the analogous residue in the essential S. 
cerevisiae PKA isoform Tpk1p is incompatible with life, 25 
suggesting that D184 is critical for enzymatic activity18. The 
cationic K72 contacts the - and -phosphates and its 
mutation to arginine or alanine does not affect KM,ATP, but 
decreases kcat up to 840-fold, highlighting the importance of 
this residue in catalysis. K72 may also be required for 30 
formation of the active conformation by forming a salt bridge 
with E91 and sequestering E91 away from basic residues of 
the RD pocket. 
D Chemical genetics of protein kinases 
Chemical genetics of protein kinases has two aims:19, 20 (i) to 35 
identify the physiological functions of protein kinases, and (ii) 
to identify all substrates for a given protein kinase. Common 
to both aims is the use of an engineered protein kinase, in 
which a large hydrophobic or polar residue in the adenine-
binding pocket in the kinase domain (Fig. 2) has been mutated 40 
to a smaller amino acid, such as alanine or glycine, and 
adenine-enlarged ATP analogues. Cell permeable ATP 
analogues lacking the triphosphate group are used to identify 
physiological roles of the protein kinase in a temporally-
controlled manner. Base-enlarged ATP analogues carrying 45 
transferable -phosphate groups are used to identify substrates 
for the protein kinase. 
 Mutation of a large hydrophobic or polar residue contacting 
the N6 position of ATP generates access to an aryl pocket 
immediately behind the ATP binding pocket21. For this 50 
reason, this residue, which is conserved in most protein 
kinases as a large or polar amino acid22, has been termed the 
‘gatekeeper’ residue. Gatekeeper mutations decrease 
interactions between the adenine ring and the adenine-binding 
pocket of the protein kinase, and as a consequence decrease 55 
the affinity of the kinase for ATP ~10 fold23. However, the 
resulting KM values remain well below the cellular ATP 
concentration of 1-3 mM. For example, the KM value for ATP 
of engineered Rous sarcoma virus tyrosine kinase (v-Src) rises 
from 12 to 150 M.23 Therefore, mutation of the gatekeeper 60 
residue is not expected to affect kinase activity in vivo. 
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Fig. 2 Competitive binding of ATP and adenine-enlarged ATP to WT and 
as-kinases is the principle underlying chemical genetics of protein kinases 
developed by Shokat and co-workers. A Binding of ATP to WT kinases is 65 
unaffected allowing unlabelled phosphate to be transferred to substrates 
of WT kinases. B Adenine-enlarged A*TP binds effectively to as-kinase, 
for example M121A PKA, allowing labelled phosphate to be transferred 
to substrates of as-kinase alone. C Affinity of ATP for as-kinase is 
reduced compared to WT kinase, reducing competition between ATP and 70 
the adenine-enlarged A*TP for as-kinase active site. D Binding of 
adenine-enlarged A*TP to WT kinases is precluded on steric grounds. 
 The enlarged adenine binding site can be filled by 
providing an ATP analogue with a bulkier, hydrophobic 
adenine moiety. These ATP analogues can engage in 75 
additional hydrophobic and van-der-Waals interactions with 
the enlarged adenine binding pocket and, thus, display an 
increased affinity for the as-kinase compared to ATP. At the 
same time, the bulkier heterocyclic ring systems preclude 
interaction of these ATP analogues with the ATP binding 80 
pockets of most other endogenous protein kinases or adenine 
nucleotide utilising enzymes. For example, a series of 
enlarged adenine analogues (analogous to those outlined in 
Scheme 3) was found to have IC50 values for WT v-Src or Fyn 
kinase of >300 M24, strongly suggesting that they had no 85 
effect on other endogenous kinases. Mutation of the 
gatekeeper residue decreased IC50 30-50 fold meaning that the 
as-kinase was selectively inhibited.24 In summary, the 
biochemical data characterising the interactions of WT and 
as-kinases with ATP and adenine-enlarged ATP analogues 90 
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(Fig. 2) form the basis of the idea that as-kinases are fully 
functional in cells; and that these kinases can either be 
selectively inhibited by providing base-enlarged ATP 
analogues that lack transferable phosphoryl groups, or can 
selectively transfer the -phosphate group of ATP analogues 5 
carrying triphosphate groups onto their substrates. 
Synthesis of as-kinase inhibitors 
Adenine-enlarged ATP analogues lacking the triphosphate 
group of ATP have been prepared, and they function as 
selective inhibitors of as-kinases (Scheme 3, R´=tBu; R= 10 
substituted phenyl, naphthyl or -CH2-aryl). Owing to the 
absence of triphosphate groups these compounds are 
membrane-permeable and have been used to inhibit an as-
kinase in intact yeast or mammalian cells, and have even been 
fed to mice to inhibit the as-kinase in situ.25 15 
 Many kinase inhibitors aim to mimic the adenine portion of 
ATP through the use of fused aza-heterocycles that show 
membrane permeability. There are many well-established 
routes for the preparation of aza-heterocycles and these can 
also be equally well applied to the preparation of as-kinase-20 
targeted inhibitors. Most synthetic routes towards as-kinase 
inhibitors use nitrogen nucleophiles in combination with 
carbonyl-, cyano- or electron-deficient aromatic electrophiles, 
and a few illustrative synthetic examples are cited below. 
Hanefeld’s method for the preparation of [3,4-d]pyrimidines, 25 
which have been used widely as as-kinase inhibitors, 
exemplifies the ease with which adenine analogues can be 
constructed (Scheme 3).26 
NC CN
O
R
CN
CN
OMe
R
CN
CN
N
N
NH2
CN
R'
RN
N
N
N
NH2R
R'
(i) (ii)
(iii)
(iv)
 
Scheme 3 Hanefeld’s method for the preparation of substituted adenine-30 
analogues. (i) NaH, RCOCl; (ii) Me2SO4, reflux; (iii) H2NNHR´, NEt3, 
reflux; (iv) formamide, reflux. 
Sandford’s use of highly electron-deficient pyridine 
precursors illustrates the scope of sequential nucleophilic 
aromatic substitutions for the preparation of aza-heterocycles 35 
(Figure 3A),27 using chemistry that is sufficiently robust to be 
used in simple flow systems.28 Recently, a mixture of 
organolithium, carbonyl and nucleophilic aromatic 
substitution methods has allowed automated, multistep 
synthesis of a small library of potential kinase inhibitors, 40 
based on imidazo[1,2-b]pyridazines, using a microflow 
reactor (Figure 3B).29 Taken together, these examples give a 
clear indication of the scope of simple, reliable chemical 
methods for the preparation of potential as-kinase inhibitors 
that can be used to selectively modulate the activities of 45 
chosen kinases. The limiting factor in the application of these 
potential inhibitors is the ability to screen libraries of 
compounds to determine their inhibition characteristics and 
selectivity towards a given as-kinase system. 
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Fig. 3 A An example of an aza-heterocycle system assembled by 
sequential nucleophilic aromatic substitution steps. B Aza-heterocyclic 
scaffold for a range of potential kinase inhibitors assembled using flow 
chemistry.  
Synthesis and use of ATP analogues with substrate properties 55 
in as-kinase systems 
Base-enlarged analogues with a transferable -phosphoryl-
group are used to identify unknown substrates of a given as-
kinase by exploiting the enlarged active site’s selectivity 
toward systems containing enlarged bases. In the simplest 60 
cases, it is possible to generate enlarged adenine nucleoside 
phosphates directly from phosphorylated adenosine systems 
through alkylation of the adenine and subsequent Dimroth 
rearrangement to give N6-alkylated-5´-phosphorylated 
adenosines (Scheme 4).30 65 
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Scheme 4 Direct alkylation of the N6-position of ATP. 
 However, the preparation of  nucleotide triphosphates and 
their analogues is often a much more laborious task, even 
though clear, prescriptive procedures are available.31 70 
 Usually, the assembly of ATP analogues can be broken 
down into two major disconnective steps; (i) preparation of 
the modified nucleoside, and (ii) elaboration to the 
triphosphate or its analogue (Scheme 5). These two 
conceptual steps will be considered in turn by way of a small 75 
selection of representative examples. 
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Scheme 5 Retrosynthetic analysis of modified ATP. 
Preparation of base-modified adenosine analogues 
Routes to adenine analogues can be loosely categorised into 
three classes. Conceptually, the simplest approach employs 5 
the use of alkylating agents for the modification of the 
exocyclic N6-position of adenosine32 or even ATP30 (Scheme 
4) via preliminary alkylation of N1 of the adenine followed by 
Dimroth rearrangement. In addition, Dimroth chemistry can 
also be employed after preliminary oxidation of the N1-10 
position of adenosine. The resulting N-oxide can be O-
alkylated, and the intermediate can be rearranged to form a 
N6-hydroxylamine system (Scheme 6). 
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Scheme 6 Dimroth chemistry for the preparation of N6-hydroxylamines. 15 
(i) oxidation to form N1-oxide; (ii) O-alkylation of N-oxide; (iii) 
rearrangement to form N6-O-alkyl hydroxylamine. 
Secondly, nucleophilic aromatic substitution of a leaving 
group from the C6-atom on an adenosine-based precursor, 
such as 6-chloropurine, by good nucleophiles is also a well-20 
established approach towards modification at the 6 position of 
the purine ring (Scheme 7).32  
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Scheme 7 Displacement of 6-chloro-group by an amine nucleophile. 
Finally, an adenine analogue can be assembled as a stand-25 
alone entity before being added to the ribose ring via a 
glycosylation procedure. For example, Shokat and co-workers 
have employed Hanefeld’s pyrazolopyrimidine synthesis to 
assemble a series of adenine analogues which have then been 
glycosylated using a protected D-ribose system to generate 30 
base-enlarged adenosine analogues. (Scheme 8).33 
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Scheme 8 Construction of base-enlarged adenosine analogues from 
pyrazolopyrimidines. R= -iPr, -Ph, -Bn, -CH2-(1)Np. Reagents: (i) SnCl4; 
(ii) NH3 in MeOH. 35 
Once assembled, the adenosine system must be 
phosphorylated. 
Phosphorylation 
Whilst many procedures are available for the preparation of 
triphosphate analogues,31, 34 we will focus on two widely 40 
adopted approaches. In the first, a nucleoside diphosphate is 
assembled, then converted to the triphosphate analogue using 
enzymatic methods. In the second, a triphosphate is 
chemically ligated to a modifying group to generate the 
triphosphate analogue. 45 
 Diphosphates can be accessed by several routes, however, 
two commonly used routes will be discussed in detail here: ( i) 
Yoshikawa phosphorylation of the modified adenosine 
followed by introduction of the second phosphoryl group 
through the use of tri- or tetraalkylammonium salts of 50 
inorganic phosphate, and (ii) preparation of a 5´-tosylate of 
the adenosine analogue and subsequent displacement of this 
leaving group using a tri- or tetraalkylammonium salt of the 
inorganic pyrophosphate ion (Scheme 9).  
 When employing the Yoshikawa route, the adenosine 55 
substrate must be dissolved in dry trialkyl phosphate solvent. 
Phosphorus oxychloride is then introduced in excess, often 
with a tertiary amine base that neutralises the acid that is 
evolved.31 When following the Poulter route,35 protection of 
the 2´/3´-cis-diol system of the adenosine substrate is usually 60 
required in order to ensure exclusive 5´-tosylation, which adds 
protection and deprotection steps to this route. At this stage, 
both routes require sources of mono- or di-phosphate 
nucleophiles, which must be soluble in organic solvents. In 
order to overcome the intrinsic insolubility of metal salts of 65 
phosphates in organic solvents, ion exchange procedures are 
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used to prepare tri- or tetraalkylammonium salts that show 
improved solubility in organic solvents. Preparation of the 
alkylammonium salts is a laborious task, however, some 
systems are commercially available. The mono- or 
diphosphate-sources must be scrupulously dry before addition 5 
to the nucleoside-monophosphodichloridate intermediate or 
the 5´-tosylate, and this drying is achieved through time-
consuming repeated evaporations with dry pyridine.  
 Crude reaction mixtures from both procedures usually 
require extensive chromatographic purification. Crude 10 
mixtures from the Poulter route are usually less complex, 
however, attempts towards the preparation of diphosphates via 
the Yoshikawa route often result in complex mixtures of 
mono-, di- and triphosphates that present a significant 
chromatographic challenge.36  15 
 Other approaches towards the assembly of di- and 
triphosphates use phosphoramidates, such as morpholidates,37 
or carbonyl diimidazole (CDI)38 as agents for the formation of 
phospho-anhydrides. There is usually a requirement for 
scrupulously dry conditions that must be maintained for long 20 
reaction times. Furthermore, tri- or tetraalkylammonium salts 
of phosphates and careful, time-consuming chromatography 
steps are also needed, and, even then, these efforts are often 
poorly rewarded with moderate yields.39 
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Scheme 9 Preparation of nucleoside diphosphates. 
Enzymatic labelling of the triphosphate group 
Base-enlarged ATP analogues labelled with a -32P- 
phosphoryl group or a -thiophosphoryl group are 
conveniently prepared by nucleoside diphosphate kinase 30 
(NDPK)-mediated transfer of a labelled phosphoryl group 
from -32P-ATP or -S-ATP. NDPK operates via a ping-pong 
mechanism where the labelled phosphoryl group is first 
transferred from the donor ATP substrate to N1 of an active 
site histidine giving a phosphoryl-enzyme intermediate. After 35 
dissociation of the ADP by-product from the phosphorylated 
active site, the base-enlarged ADP substrate binds and the 
labelled phosphoryl group is then transferred to give the 
labelled, base-enlarged ATP analogue.33 Immobilisation of 
NDPK on a solid support can be used to ensure that excess 40 
labelled ATP donor and ADP by-product can be fully 
removed before introduction of the base-enlarged ATP 
analogue. It is essential to avoid the presence of ATP donor 
because this could be used by non-as-kinases and lead to false 
positives. 45 
 ATP analogues labelled with a -32P-phosphoryl group and 
-thiophosphoryl group have been used by Shokat and co-
workers. In the case of v-Src the catalytic efficiency (kcat/KM) 
of an as-kinase with -32P-N6-cyclopentyl-ATP as substrate 
was indistinguishable from the catalytic efficiency of the WT 50 
kinase with ATP.23, 40 Subsequently, -32P-based triphosphate 
analogues derived from Hanefeld’s pyrazolpyrimidines 
(Scheme 8) have also been used.33 -32P-based systems have 
several disadvantages. Firstly, detection and isolation of 
labelled proteins requires the use of 2D gel methods. 55 
Isoelectric focussing conditions in the first dimension have to 
be carefully chosen to minimize bias against highly acidic or 
basic proteins. Buffers to solubilize transmembrane proteins 
have to be carefully optimised to maximise solubility of these 
proteins in gel-based analysis systems. Secondly, 32P-60 
phosphorylated substrates are susceptible to hydrolysis by 
phosphatases, which decreases sensitivity and may introduce 
bias. 
 The use of chemically labelled -phosphates promises to 
circumvent some of these technical limitations. The most 65 
obvious choice to label the -phosphate is replacement of one 
terminal oxygen atom by a sulfur atom in -S-ATP. The 
nucleophilic sulfur anion of the thiophosphate, when 
transferred to a substrate protein, offers a ‘handle’ for affinity 
purification, bioconjugation or, indeed, a combination of these 70 
methods. Furthermore, thiophosphates are more resistant to 
hydrolysis by phosphatases, thus, once formed, 
thiophosphopeptides are more likely to be detected than 
phosphopeptides. In addition, -S-ATP is not readily accepted 
as a substrate by ATPases and adenine-enlarged -S-ATP 75 
analogues can be generated with relative ease using NDPK as 
described above. 
 Simple reversible thiol affinity chromatography of systems 
that have been exposed to base-enlarged--S-ATP analogues, 
where captured thiophosphorylated peptides are released via 80 
disulfide reduction, is limited by the fact that cysteine-
containing proteins are also likely to be captured. Judicious 
control of pH can be used to attenuate the reactivity of thiols 
in comparison to thiophosphates,41 however, selective release 
of thiophosphorylated peptides from a capture resin represents 85 
a more reliable strategy. This approach was adopted in 
parallel by Blethrow et al. and Chi et al., who used different 
thiol-affinity resins and release strategies in order to 
accomplish this goal (Scheme 10). Blethrow et al. chose to 
capture both thiophosphorylated peptides and cysteine-90 
containing peptides after digestion of a pool of potential 
substrates.42 An iodoacetyl resin was employed, which led to 
the formation of carbon-sulfur bonds. In the case of the 
thiophosphate system, the resulting S-bridging phosphodiester 
was susceptible to hydrolysis after oxidation of the sulfur 95 
atom. On the other hand, the thioethers resulting from capture 
of cysteine-containing peptides were oxidised to stable 
sulfoxides that remained attached to the affinity resin (Scheme 
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10A). Chi et al. captured both thiophosphorylated peptides 
and cysteine-containing peptides after digestion, however, a 
thiopyridyl disulfide resin was employed in order to form 
mixed disulfides between the resin and thiophosphopeptides 
or cysteine-containing peptides.43 The mixed disulfides 5 
between simple thiols (on the resin) and thiophosphoryl 
groups are labile under basic conditions, however, simple 
mixed disulfides between resin and cysteine groups are not, 
thus, thiophosphopeptides were selectively eluted from the 
affinity resin (Scheme 10B). In a third approach, Allen et al. 10 
chose to alkylate the nucleophilic thiophosphate ion and then 
used antibodies raised against an O-thiophosphorylated, S-
alkylated thiophospho-threonine-based hapten to 
immunoprecipitate thiophosphorylated, alkylated kinase 
substrates (Scheme 10C).44 15 
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Scheme 10 Methods for selective purification of thiophosphorylated proteins and peptides. Green semi-circles represent thiophosphoproteins, green lines 
digested phosphoprotein fragments, red semi-circles non-thiophosphorylated proteins contained cysteine residues, red lines digested protein fragments 
derived from these proteins and cyan circles represent affinity matrices. Blue lines represent antibodies raised against S-(p-
nitrobenyl)thiophosphopeptides.20 
Chemical labelling of the triphosphate group 
Green and Pflum extended the use of -modified ATP 
analogues by using a -biotinyl-ATP 1 (Scheme 11A).45 This 
approach relied upon the open nature of the active sites of 
many kinases around the position of the -phosphoryl group of 25 
ATP (Fig. 1). When -biotinyl-ATP 1 was incubated with 
protein kinase A or casein kinase 2 and their respective 
substrates, the biotinylated -phosphoryl group was 
transferred to the substrates in both cases (Scheme 11B). Once 
attached, the biotinyl group was used as an affinity tag for 30 
purification of labelled substrates. The tag was then cleaved 
from the substrates using acid to allow for identification of the 
substrate by MS. The use of a phosphoramidate-linked label 
also gave conclusive evidence that significantly elaborated -
phosphoryl groups can be transferred by kinases. This result is 35 
initially surprising given the differenccs in mechanisms of 
phosphoryl group transfer between phosphate mono- and 
diesters. The fact that phosphoramidate-based -groups can be 
transferred can perhaps be explained by virtue of the fact that 
the -amino group is likely to be protonated at the pHs that are 40 
used in labelling assays. This, in turn, probably leads to an 
increase in the electrophilicty of the adjacent phosphoryl 
group and a more dissociative mechanism for phosphoryl 
tranfer being retained,46 with the net result being only minor 
reductions in observed kcat values (see dansyl systems below).  45 
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Scheme 11 A -biotinyl-ATP 1. B Green and Pflum's use of -biotinyl-
ATP 1 in kinase catalysed biotinyl-phosphate transfer for kinase substrate 
isolation. (i) -biotinyl-ATP 1 and kinase, (ii) affinity chromatography 
then CF3CO2H. 5 
 In further extensions of this approach, Pflum and co-
workers have developed ATP analogues with fluorophore- and 
photo-probe-modified -phosphoryl groups in the form of 
dansyl- and azido-phosphoramidates, respectively.47, 48 The 
dansyl-ATP system was obtained commercially, whereas, the 10 
azide was prepared via carbodiimide-based coupling of ATP 
to an amino-based linker connected to an aryl azide. With the 
dansyl system, efficient dansylation of both peptide and 
protein substrates was demonstrated where only relatively 
small reductions in kcat values (~6-25-fold) were observed. 15 
With the azide system, a given kinase can transfer the azide-
modified phosphoryl group to a substrate, then, when 
photolysed, the azide gives a reactive intermediate that can 
cross-link to the kinase. In this way, a covalent link can be 
established between a given kinase and its substrate(s) to form 20 
a high molecular weight complex between the kinase and 
substrate which migrates as a single entity during gel 
electrophoresis. The substrate and kinase components can then 
be identified using classical blotting techniques.47 
 Gouverneur and co-workers49 have also developed 25 
phosphoramidate-based azide- and alkyne--modified ATP 
analogues that can be used for ‘click’-style cycloadditions and 
Staudinger ligations. These functional groups provide handles 
for further modification, such as addition of an affinity 
purification tag, when the -phosphoryl has been transferred 30 
to a peptide substrate. Synthetic methods were based on CDI 
activation of ATP followed by reaction of the activated ATP 
with a functionalised amine. In addition, phosphoester-based, 
rather than phosphoramidate-based, systems were also 
explored, and these were prepared by sequential 35 
phosphorylation of a functionalised alcohol followed by 
ligation of the resulting phosphate to ADP using CDI. Despite 
the expected difference in reactivity of the phosphoester-
based substrates, phosphorylation of p27kip1 by CDK2 could 
be shown using an antibody against phosphorylated p27kip1.49 40 
Considering the tight steric requirements of the 
phosphospecific antibody during selective recognition of 
phosphorylated epitopes, these results are surprising and may 
require confirmation using more sensitive techniques, such as 
MS. 45 
Limitations of as-kinases 
as-Kinases are powerful tools for identifying kinase substrates 
and the functions of protein kinases. The methodology is, 
however, limited by (i) mutation of the gatekeeper 
inactivating some protein kinases; (ii) a few kinases 50 
possessing alanine or glycine as the gatekeeper amino acid,50 
(iii) provision of the as-kinase at endogenous expression 
levels, and as the sole source for the kinase; (iv) competition 
between ATP and adenine-enlarged ATP analogues in cell 
lysates as phosphate donors, (v) the membrane impermeability 55 
of charged ATP analogues (vi) and the rapid hydrolysis and 
reincorporation of their labelled phosphates into nucleotides. 
 Considerations (i), (ii) and (iii) affect the use of ATP 
analogues that lack transferable phosphoryl groups when 
trying to identify physiological functions of the as-kinase. 60 
Limitation (i) is significant because loss of control over the 
time point of inactivation of the as-kinase by administration 
of the inhibitor largely eliminates the advantage that the use 
of as-kinases promises compared to classical approaches 
based on kinase-inactivating amino acid mutations. Limitation 65 
(ii) indicates that interpretation of data arising from inhibition 
of as-kinases may not be foolproof. 
 Identification of so-called ‘second-site suppressors’ has 
gone some way towards addressing problems with as-kinases 
that do not tolerate mutation of the gatekeeper residue. 70 
Mutation of the gatekeeper residue in G protein-coupled 
receptor kinase 2 (GRK2), cell division cycle 5 (cdc5) kinase, 
or MEK kinase 1 destroyed kinase activity.40, 50 Nevertheless, 
the activity of these mutant kinases was restored by ‘second 
site suppressor’ mutations. These second-site suppressors can 75 
be identified using random PCR mutagenesis screens ideally 
coupled to a phenotypical read-out in E. coli,50 yeast, or 
another genetically traceable organism. Alternatively, 
candidates for second-site suppressors may be rationally 
identified by comparing residues lining the ATP-binding 80 
pocket (Figure 1).40 
 Identification of as-kinase substrates is affected by all six 
potential limitations. Provision of the as-kinase in excess over 
its normal expression level may lead to the identification of 
low affinity, false positive substrates. Depending on the 85 
organism, expression of the as-kinase at endogenous 
expression levels to minimize identification of false positive, 
low affinity substrates and to retain spatial, temporal, or 
developmental control over activity of the as-kinase may also 
be challenging. For inhibition studies, the as-kinase also 90 
needs to be the sole source of the chosen kinase activity. 
Homologous recombination to replace the WT allele by the 
as-allele can be used in organisms displaying high frequencies 
of homologous recombination, for example certain yeast 
species.51 The relatively simple gene and promoter structures 95 
in these organisms greatly facilitate near endogenous 
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expression of as-alleles on single copy plasmids in cells 
harbouring a chromosomal deletion of the gene encoding the 
kinase of interest51. This latter approach is not available for 
mammalian cells, therefore as-kinases have been mostly used 
in yeast.22, 52-57 In mammalian cells, as-kinases have been 5 
used to study kinases whose overexpression confers 
phenotypes.40, 58 For example, inhibition of the transforming 
as-kinase v-erbB-as1 with 1NA-PP1 (Scheme 3, R=1-
naphthyl, R´= tBu) inhibited the transforming properties of 
this kinase.58 10 
 Homologous recombination in murine embryonic stem cells 
can be used to generate mice carrying the as-allele in the 
chromosomal position of the WT allele. Cell lines, usually 
embryonic fibroblast lines, can be established from these 
mice. For differentiated cell types this approach often may not 15 
yield sufficient material for biochemical searches for as-
kinase substrates. In addition, generation of these mice is 
expensive, time-consuming, and laborious. Zinc finger 
nucleases (ZFNs), which have been designed to bind to and 
introduce a DNA strand break near a specific DNA sequence, 20 
yield frequencies of homologous recombination of 1-20% in 
yeast, plant, and mammalian cells.59, 60 Co-transfection of a 
vector expressing a ZFN and a donor vector providing the 
cDNA for the as-kinase can be used to integrate the as-allele 
into upstream exons of the kinase gene. Alternatively, the 25 
gatekeeper mutation can be introduced directly into the 
chromosomal locus. 
 ATP analogues containing phosphate groups cannot cross 
the cell membrane because of their charged nature, therefore, 
substrates are often identified in cell lysates. Permeabilisation 30 
of cell membranes with low concentrations of the detergent 
digitonin is a well-established technique and allows ATP 
analogues to enter the cell.61 Permeabilisation conditions can 
be chosen in such a way as to deplete intracellular ATP 
concentrations, which is important to ensure that relatively 35 
small, possibly micromolar concentrations of the ATP 
analogue, can successfully compete for the as-kinase against 
endogenous millimolar concentrations of ATP. 
Permeabilisation also offers advantages over cell lysis, 
because cells often exert spatial control over kinases by 40 
separating kinase and substrate in separate compartments. Of 
course, upon lysis this spatial control is lost. 
 However, significant problems remain with using ATP 
analogues in cell lysates or permeabilized cells. Cellular ATP, 
if not efficiently removed, may efficiently compete with 45 
precious base-enlarged ATP analogues as phosphate donor, 
because of its high concentration in cells. Conceptually, ATP 
can be excluded from the nucleotide binding pocket of an as-
kinase by introducing bulkier amino acids contacting other 
portions of the adenine system. These secondary mutations are 50 
then compensated for by excavating the adenine system. 
Progress towards these design aims has been made with the 
development of N4-benzyl-5-aminoimidazole-4-carboxamide 
ribotide triphosphate, which is accepted by an as-kinase, but 
not by the corresponding WT kinase.62, 63 55 
 Hydrolytic release of the -phosphate from ATP analogues 
such as N6-phenylethyl--32P-ATP, catalysed by apyrases or 
ATPases, occurs in <1 min.61 The liberated phosphate can be 
reincorporated into the cellular ATP pool in <0.1 s,64-66, for 
example by NDPKs, resulting in label dispersion, and a 60 
substantial non-specific background. -S-ATP is resistant to 
hydrolysis by ATPases and some apyrases,67 but is a substrate 
of NDPKs. Not all kinases readily accept -S-ATP as 
substrate.44, 48 Thus, further research is required to optimise 
the performance of ATP analogues to screen for as-kinase 65 
substrates. 
E Activity-based profiling of active protein kinases 
In addition to identifying the physiological roles and 
substrates of all protein kinases, knowledge about which 
kinases are active in a given experimental setting, for example 70 
cancer cells or after exposure of cells to a stimulus, is also 
valuable. This latter knowledge can be obtained by using 
activity-based profiling of kinases68 by exploiting regulation 
of the activity of many protein kinases by controlling access 
of ATP to the ATP binding pocket through movement of the 75 
activation loop. To identify active kinases cell lysates or 
permeabilised cells are incubated with an ATP analogue, such 
as  such as -acyl-biotin-ATP 2 (Scheme 12).69 Synthesis of -
acyl-biotin-ATP 2, was accomplished via activation of N-(+)-
biotinyl-6-aminohexanoic acid via the chloroformate method 80 
followed by ligation of the activated biotin system to the 
organic solvent-soluble triethylammonium salt of ATP under 
anhydrous conditions in dipolar aprotic solvent to form a 
mixed phosphoric-carboxylic acid anhydride. 
 After labelling, affinity techniques were used to isolate 85 
biotin-labelled proteins or peptides for identification and 
quantification through MS-based techniques. This approach 
was also used to determine the selectivity of protein kinase 
inhibitors towards a given protein kinase through competition 
studies13. -Acyl-biotin-ATP labels one of two active sites 90 
lysines corresponding to K72 and K168 in PKA. K72 is 
conserved in ~98% of the protein kinases, whereas K168 is 
less well conserved.70 Both ATP- and ADP-derived 
biotinylating agents were used to label >80% of the predicted 
kinases in cancer cells, indicating that the majority of protein 95 
kinases are active in this experimental setting. Rules 
predicting whether the K72 or K168 analogous residues are 
preferentially labelled by -acyl-biotin-ATP or -acyl-biotin-
ADP have not yet been developed. 
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Scheme 12 Kozarich's kinase active site-directed biotinylation strategy 
for the isolation of kinases. The active site lysine that is labelled 
corresponds to either K72 or K168 in PKA. 
Conclusions 5 
Examples of genetic and classical approaches towards 
identification of kinase-substrate pairs were used to illustrate 
the power and limitations of these approaches. In order to 
address some of these limitations, chemical genetic 
approaches have been adopted, and these are currently gaining 10 
prominence in the area of kinomics. New developments, 
particularly with respect to addressing the problems 
associated with the preparation of nucleotides, should 
overcome some of the obstacles that limit the application of 
these approaches at present. The development of new, less 15 
disruptive approaches towards delivery of charged nucleotide 
systems through cell walls will remove a significant limitation 
to the chemical genetic approach where currently cell 
permeability limits applications to lysates or other in vitro 
systems where spatial control over the action of kinases is 20 
lost. However, extension to mammalian systems where 
biomedical targets can be assessed more robustly will truly 
allow this field of chemical genetics to achieve its full 
potential. 
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